Table 3:

Multivariable analysis of odds of study outcomes for anti-TNF compared to vedolizumab)

(a) Crohn’s disease
Outcome	Multivariable odds ratio+	95% confidence interval	P-value
Remission at 3 months	2.82	1.18 – 6.76	0.03
Remission at 6 months	1.34	0.62 – 2.88	0.58
Remission at 12 months	0.79	0.35 – 1.79	0.57
Infection at 1 year	1.00	0.37 – 2.73	0.89
(b) Ulcerative colitis
Outcome	Multivariable odds ratio+	95% confidence interval	P-value
Remission at 3 months	1.74	0.74 – 4.13	0.29
Remission at 6 months	1.69	0.73 – 3.91	0.38
Remission at 12 months	1.68	0.67 – 4.18	0.27
Infection at 1 year	1.89	0.61 – 5.78	0.31

⁺Adjusted for type of IBD, combination immunomodulator use, race/ethnicity, and site of recruitment